Overview
Updated 14 Jul 2026
Suzanne George, MD, is Chief, Division of Sarcoma at Dana-Farber Cancer Institute. The public record shows 634 publications with 21,229 citations (h-index 74), centered on Colorectal Cancer, Sarcoma. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 6 companies, 2 NIH-funded awards (2015–2025).
- Most recent indexed publication: 2026 · JCO precision oncology
- Top research focus: Colorectal Cancer
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 29 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Sponsor: Dana-Farber Cancer Institute
InvestigatorPhase 2RecruitingNCT07467772 - PH 2 Pemigatinib in SDH-deficient GIST
Sponsor: Dana-Farber Cancer Institute
InvestigatorPhase 2RecruitingNCT07434843 - A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Sponsor: SEED Therapeutics, Inc.
InvestigatorPhase 1RecruitingNCT07197554
Industry payments
Updated 14 Jul 2026
6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20251 payment
- Deciphera Pharmaceuticals Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
NIH funding
Updated 14 Jul 2026
2 NIH research awards on record, funded 2015–2025 per NIH RePORTER. The latest:
- Count Me In: Partnering with patients to define the clinical and genomic landscape of rare aggressive sarcomas in children and adults
Broad Institute, Inc.
FY2025$3,418,624U2CCA252974 - Count Me In: Partnering with patients to define the clinical and genomic landscape of rare aggressive sarcomas in children and adults
Broad Institute, Inc.
FY2024$2,950,685U2CCA252974 - Alliance for Clinical Trials in Oncology Operations Center - GY10 BIQSFP Supplement
Brigham and Women'S Hospital
FY2023$2,824,605U10CA180821
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma.
Clinical cancer research
2026 - Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.
Clinical cancer research
2026
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
450 Brookline Avenue, Boston, MA 02215
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- MD
University of Massachusetts Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →allianceforclinicaltrialsinoncology.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →allianceforclinicaltrialsinoncology.org ↗
- President
Alliance for Clinical Trials in Oncology Foundation; President, Alliance NCTN Foundation; President, Alliance Foundation Trials, LLC; President, Alliance Innovation DataLab
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →allianceforclinicaltrialsinoncology.org ↗
Awards & honorshonors on the public record
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
Secondary affiliationsappointments beyond the home institution
- Brigham and Women's Hospital
Medical Oncology (Sarcoma and Bone Cancer Treatment Center)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →physiciandirectory.brighamandwomens.org ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/suzanne-george-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by otherswhere others cite or feature them
- Other
onclive.com/authors/suzanne-george-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - X / Twitter
x.com/SarcomaAlliance/status/1095291451519324161
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Richardson, MD
Harvard University
- 2,062
- publications
- 172
- h-index
- 17
- trials
Pasi Janne, MD, PhD
Harvard University
- 2,385
- publications
- 163
- h-index
- 15
- trials
Steven Greenberg, MD
Harvard University
- 954
- publications
- 144
- h-index
- 9
- trials
David Scadden, MD
Harvard University
- 665
- publications
- 124
- h-index
- 4
- trials